MAP1LC3B and prostate carcinoma: Regarding LC3B, the present study found that 56.4% of prostatic carcinoma cases showed LC3B positivity, and this disagreed with Falasca et al. (2015) (26), who demonstrated an 88% increase in the level of LC3B protein in prostatic carcinoma cases.